MetaVia is trading higher in pre-market with no identified company-specific catalyst, up 4.1% at $1.54. - That compares with the October 6 close of $1.48. - The latest listed release was September 9, about preclinical findings for DA-1726. - The broader context was risk-off, with major U.S. indices lower; available evidence does not establish a link to MetaVia’s move higher.